CA2696833A1 - Disease treatment via antimicrobial peptides or their inhibitors - Google Patents

Info

Publication number

CA2696833A1

CA2696833A1 CA2696833A CA2696833A CA2696833A1 CA 2696833 A1 CA2696833 A1 CA 2696833A1 CA 2696833 A CA2696833 A CA 2696833A CA 2696833 A CA2696833 A CA 2696833A CA 2696833 A1 CA2696833 A1 CA 2696833A1

Authority

CA

Canada

Prior art keywords

disease

cathelicidin

inflammatory

autoimmune

cell

Prior art date

2007-07-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 193
• 201000010099 disease Diseases 0.000 title claims abstract description 191
• 238000011282 treatment Methods 0.000 title claims abstract description 109
• 102000044503 Antimicrobial Peptides Human genes 0.000 title abstract description 247
• 108700042778 Antimicrobial Peptides Proteins 0.000 title abstract description 247
• 239000003112 inhibitor Substances 0.000 title abstract description 42
• POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 claims abstract description 181
• 108060001132 cathelicidin Proteins 0.000 claims abstract description 153
• 102000014509 cathelicidin Human genes 0.000 claims abstract description 134
• 239000012634 fragment Substances 0.000 claims abstract description 70
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 107
• 150000001875 compounds Chemical class 0.000 claims description 96
• 230000004054 inflammatory process Effects 0.000 claims description 87
• 206010061218 Inflammation Diseases 0.000 claims description 86
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 50
• 230000002757 inflammatory effect Effects 0.000 claims description 48
• 208000027866 inflammatory disease Diseases 0.000 claims description 46
• 206010003246 arthritis Diseases 0.000 claims description 44
• 206010012601 diabetes mellitus Diseases 0.000 claims description 35
• 208000023275 Autoimmune disease Diseases 0.000 claims description 34
• 239000008194 pharmaceutical composition Substances 0.000 claims description 34
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 34
• 208000008589 Obesity Diseases 0.000 claims description 30
• 235000020824 obesity Nutrition 0.000 claims description 30
• 150000001413 amino acids Chemical class 0.000 claims description 28
• 230000005784 autoimmunity Effects 0.000 claims description 27
• 239000000203 mixture Substances 0.000 claims description 27
• 230000001363 autoimmune Effects 0.000 claims description 26
• 201000001245 periodontitis Diseases 0.000 claims description 26
• 239000004480 active ingredient Substances 0.000 claims description 25
• 201000004681 Psoriasis Diseases 0.000 claims description 24
• 206010022489 Insulin Resistance Diseases 0.000 claims description 23
• 208000001132 Osteoporosis Diseases 0.000 claims description 22
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 21
• 201000006417 multiple sclerosis Diseases 0.000 claims description 20
• 239000003814 drug Substances 0.000 claims description 19
• 210000000988 bone and bone Anatomy 0.000 claims description 18
• 201000008482 osteoarthritis Diseases 0.000 claims description 18
• 230000001684 chronic effect Effects 0.000 claims description 17
• 230000004048 modification Effects 0.000 claims description 16
• 238000012986 modification Methods 0.000 claims description 16
• 239000003937 drug carrier Substances 0.000 claims description 13
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims description 12
• 208000027418 Wounds and injury Diseases 0.000 claims description 12
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 11
• 206010052428 Wound Diseases 0.000 claims description 11
• 238000002360 preparation method Methods 0.000 claims description 11
• 108700022109 ropocamptide Proteins 0.000 claims description 11
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 10
• 201000002481 Myositis Diseases 0.000 claims description 10
• 206010053555 Arthritis bacterial Diseases 0.000 claims description 9
• 201000004624 Dermatitis Diseases 0.000 claims description 9
• 206010031252 Osteomyelitis Diseases 0.000 claims description 9
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 9
• 206010008027 Cerebellar atrophy Diseases 0.000 claims description 8
• 208000011231 Crohn disease Diseases 0.000 claims description 8
• 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 8
• 208000025255 bacterial arthritis Diseases 0.000 claims description 8
• 201000001119 neuropathy Diseases 0.000 claims description 8
• 230000007823 neuropathy Effects 0.000 claims description 8
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 8
• 201000004384 Alopecia Diseases 0.000 claims description 7
• 206010008642 Cholesteatoma Diseases 0.000 claims description 7
• 208000012902 Nervous system disease Diseases 0.000 claims description 7
• 208000025966 Neurological disease Diseases 0.000 claims description 7
• 206010072148 Stiff-Person syndrome Diseases 0.000 claims description 7
• 125000000539 amino acid group Chemical group 0.000 claims description 7
• 210000003041 ligament Anatomy 0.000 claims description 7
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
• 206010065687 Bone loss Diseases 0.000 claims description 6
• 201000011152 Pemphigus Diseases 0.000 claims description 6
• 201000008937 atopic dermatitis Diseases 0.000 claims description 6
• 201000001421 hyperglycemia Diseases 0.000 claims description 6
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
• 208000011580 syndromic disease Diseases 0.000 claims description 6
• 208000018084 Bone neoplasm Diseases 0.000 claims description 5
• 206010008685 Chondritis Diseases 0.000 claims description 5
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
• 208000001640 Fibromyalgia Diseases 0.000 claims description 5
• 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 5
• 206010065159 Polychondritis Diseases 0.000 claims description 5
• 208000034943 Primary Sjögren syndrome Diseases 0.000 claims description 5
• 208000024777 Prion disease Diseases 0.000 claims description 5
• 206010039710 Scleroderma Diseases 0.000 claims description 5
• 208000000491 Tendinopathy Diseases 0.000 claims description 5
• 206010043255 Tendonitis Diseases 0.000 claims description 5
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
• 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 5
• 201000001981 dermatomyositis Diseases 0.000 claims description 5
• 208000032625 disorder of ear Diseases 0.000 claims description 5
• 210000003027 ear inner Anatomy 0.000 claims description 5
• 230000004968 inflammatory condition Effects 0.000 claims description 5
• 208000018937 joint inflammation Diseases 0.000 claims description 5
• 230000004770 neurodegeneration Effects 0.000 claims description 5
• 208000009169 relapsing polychondritis Diseases 0.000 claims description 5
• 210000002460 smooth muscle Anatomy 0.000 claims description 5
• 230000008409 synovial inflammation Effects 0.000 claims description 5
• 201000004415 tendinitis Diseases 0.000 claims description 5
• 208000026872 Addison Disease Diseases 0.000 claims description 4
• 206010001324 Adrenal atrophy Diseases 0.000 claims description 4
• 208000024827 Alzheimer disease Diseases 0.000 claims description 4
• 208000008037 Arthrogryposis Diseases 0.000 claims description 4
• 208000023328 Basedow disease Diseases 0.000 claims description 4
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
• 201000005262 Chondroma Diseases 0.000 claims description 4
• 206010008748 Chorea Diseases 0.000 claims description 4
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
• 208000006561 Cluster Headache Diseases 0.000 claims description 4
• 208000014311 Cushing syndrome Diseases 0.000 claims description 4
• 208000001840 Dandruff Diseases 0.000 claims description 4
• 208000034715 Enchondroma Diseases 0.000 claims description 4
• 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 4
• 208000015023 Graves' disease Diseases 0.000 claims description 4
• 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 4
• 206010019233 Headaches Diseases 0.000 claims description 4
• 206010020850 Hyperthyroidism Diseases 0.000 claims description 4
• 208000004575 Infectious Arthritis Diseases 0.000 claims description 4
• 208000026492 Isaac syndrome Diseases 0.000 claims description 4
• 208000000209 Isaacs syndrome Diseases 0.000 claims description 4
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims description 4
• 208000019695 Migraine disease Diseases 0.000 claims description 4
• 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 4
• 206010028424 Myasthenic syndrome Diseases 0.000 claims description 4
• 206010028665 Myxoedema Diseases 0.000 claims description 4
• 208000003435 Optic Neuritis Diseases 0.000 claims description 4
• 208000000035 Osteochondroma Diseases 0.000 claims description 4
• 208000016222 Pancreatic disease Diseases 0.000 claims description 4
• 208000018737 Parkinson disease Diseases 0.000 claims description 4
• 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
• 206010071141 Rasmussen encephalitis Diseases 0.000 claims description 4
• 208000004160 Rasmussen subacute encephalitis Diseases 0.000 claims description 4
• 208000024799 Thyroid disease Diseases 0.000 claims description 4
• 208000000323 Tourette Syndrome Diseases 0.000 claims description 4
• 208000016620 Tourette disease Diseases 0.000 claims description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
• 201000002996 androgenic alopecia Diseases 0.000 claims description 4
• 230000000469 anti-sperm effect Effects 0.000 claims description 4
• 201000004339 autoimmune neuropathy Diseases 0.000 claims description 4
• 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 claims description 4
• 208000010217 blepharitis Diseases 0.000 claims description 4
• 208000012601 choreatic disease Diseases 0.000 claims description 4
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 4
• 208000018912 cluster headache syndrome Diseases 0.000 claims description 4
• 206010014599 encephalitis Diseases 0.000 claims description 4
• 231100000869 headache Toxicity 0.000 claims description 4
• 208000000509 infertility Diseases 0.000 claims description 4
• 230000036512 infertility Effects 0.000 claims description 4
• 231100000535 infertility Toxicity 0.000 claims description 4
• 201000001441 melanoma Diseases 0.000 claims description 4
• 206010027599 migraine Diseases 0.000 claims description 4
• 206010028417 myasthenia gravis Diseases 0.000 claims description 4
• 208000003786 myxedema Diseases 0.000 claims description 4
• 230000002611 ovarian Effects 0.000 claims description 4
• 230000001575 pathological effect Effects 0.000 claims description 4
• 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 4
• 230000000750 progressive effect Effects 0.000 claims description 4
• 201000007094 prostatitis Diseases 0.000 claims description 4
• 201000001223 septic arthritis Diseases 0.000 claims description 4
• 201000000849 skin cancer Diseases 0.000 claims description 4
• 201000008261 skin carcinoma Diseases 0.000 claims description 4
• 230000002269 spontaneous effect Effects 0.000 claims description 4
• 208000021510 thyroid gland disease Diseases 0.000 claims description 4
• 206010043778 thyroiditis Diseases 0.000 claims description 4
• 208000005057 thyrotoxicosis Diseases 0.000 claims description 4
• 230000029663 wound healing Effects 0.000 claims description 4
• 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
• 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims description 3
• 208000009283 Craniosynostoses Diseases 0.000 claims description 3
• 206010049889 Craniosynostosis Diseases 0.000 claims description 3
• 208000019872 Drug Eruptions Diseases 0.000 claims description 3
• 206010056274 Erythema toxicum neonatorum Diseases 0.000 claims description 3
• 206010016936 Folliculitis Diseases 0.000 claims description 3
• 208000002966 Giant Cell Tumor of Bone Diseases 0.000 claims description 3
• 208000013016 Hypoglycemia Diseases 0.000 claims description 3
• 208000006541 Klippel-Feil syndrome Diseases 0.000 claims description 3
• 208000010191 Osteitis Deformans Diseases 0.000 claims description 3
• 201000009859 Osteochondrosis Diseases 0.000 claims description 3
• 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 3
• 208000008558 Osteophyte Diseases 0.000 claims description 3
• 208000027868 Paget disease Diseases 0.000 claims description 3
• 206010034277 Pemphigoid Diseases 0.000 claims description 3
• 208000027086 Pemphigus foliaceus Diseases 0.000 claims description 3
• 206010040954 Skin wrinkling Diseases 0.000 claims description 3
• 206010000496 acne Diseases 0.000 claims description 3
• 231100000360 alopecia Toxicity 0.000 claims description 3
• 208000026764 autoimmune bullous skin disease Diseases 0.000 claims description 3
• 201000011143 bone giant cell tumor Diseases 0.000 claims description 3
• 208000000594 bullous pemphigoid Diseases 0.000 claims description 3
• 201000010103 fibrous dysplasia Diseases 0.000 claims description 3
• 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
• 208000017169 kidney disease Diseases 0.000 claims description 3
• 201000011486 lichen planus Diseases 0.000 claims description 3
• 208000027202 mammary Paget disease Diseases 0.000 claims description 3
• 230000002503 metabolic effect Effects 0.000 claims description 3
• 208000007656 osteochondritis dissecans Diseases 0.000 claims description 3
• 208000005368 osteomalacia Diseases 0.000 claims description 3
• 208000002865 osteopetrosis Diseases 0.000 claims description 3
• 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
• 201000006409 renal osteodystrophy Diseases 0.000 claims description 3
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
• 230000037303 wrinkles Effects 0.000 claims description 3
• 208000004300 Atrophic Gastritis Diseases 0.000 claims description 2
• 206010005949 Bone cancer Diseases 0.000 claims description 2
• 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
• 208000015943 Coeliac disease Diseases 0.000 claims description 2
• 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
• 208000030814 Eating disease Diseases 0.000 claims description 2
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
• 208000036495 Gastritis atrophic Diseases 0.000 claims description 2
• 206010061459 Gastrointestinal ulcer Diseases 0.000 claims description 2
• 201000005000 autoimmune gastritis Diseases 0.000 claims description 2
• 201000001883 cholelithiasis Diseases 0.000 claims description 2
• 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 2
• 206010009887 colitis Diseases 0.000 claims description 2
• 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
• 235000014632 disordered eating Nutrition 0.000 claims description 2
• 208000001130 gallstones Diseases 0.000 claims description 2
• 208000009326 ileitis Diseases 0.000 claims description 2
• 208000028774 intestinal disease Diseases 0.000 claims description 2
• 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
• 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
• 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims 2
• 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 2
• 230000000241 respiratory effect Effects 0.000 claims 2
• 206010012434 Dermatitis allergic Diseases 0.000 claims 1
• 206010037596 Pyelonephritis Diseases 0.000 claims 1
• 208000010668 atopic eczema Diseases 0.000 claims 1
• 208000019206 urinary tract infection Diseases 0.000 claims 1
• 238000000034 method Methods 0.000 abstract description 158
• 239000003910 polypeptide antibiotic agent Substances 0.000 abstract description 151
• 239000003795 chemical substances by application Substances 0.000 abstract description 13
• 230000001939 inductive effect Effects 0.000 abstract description 11
• 230000000770 proinflammatory effect Effects 0.000 abstract description 8
• 230000035876 healing Effects 0.000 abstract description 4
• 239000000556 agonist Substances 0.000 abstract description 2
• 125000003345 AMP group Chemical group 0.000 abstract 2
• 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 abstract 2
• 210000004027 cell Anatomy 0.000 description 149
• 210000001519 tissue Anatomy 0.000 description 109
• 241000282414 Homo sapiens Species 0.000 description 66
• 241000699670 Mus sp. Species 0.000 description 63
• 230000031018 biological processes and functions Effects 0.000 description 54
• 230000001105 regulatory effect Effects 0.000 description 53
• 230000000694 effects Effects 0.000 description 49
• 238000012360 testing method Methods 0.000 description 45
• 238000002474 experimental method Methods 0.000 description 37
• 206010028980 Neoplasm Diseases 0.000 description 36
• 230000004069 differentiation Effects 0.000 description 34
• 241000699666 Mus <mouse, genus> Species 0.000 description 31
• 238000001727 in vivo Methods 0.000 description 31
• 230000002401 inhibitory effect Effects 0.000 description 28
• 239000007924 injection Substances 0.000 description 28
• 238000002347 injection Methods 0.000 description 28
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 28
• 108090000623 proteins and genes Proteins 0.000 description 28
• QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 27
• 230000014509 gene expression Effects 0.000 description 26
• 230000012010 growth Effects 0.000 description 25
• 208000026935 allergic disease Diseases 0.000 description 24
• 230000001965 increasing effect Effects 0.000 description 23
• 108020004999 messenger RNA Proteins 0.000 description 23
• 108020004459 Small interfering RNA Proteins 0.000 description 22
• 235000001014 amino acid Nutrition 0.000 description 22
• 239000002158 endotoxin Substances 0.000 description 22
• 229920006008 lipopolysaccharide Polymers 0.000 description 22
• 206010020751 Hypersensitivity Diseases 0.000 description 21
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 20
• 201000011510 cancer Diseases 0.000 description 20
• 210000000440 neutrophil Anatomy 0.000 description 20
• 230000035755 proliferation Effects 0.000 description 20
• 229930003316 Vitamin D Natural products 0.000 description 19
• 230000033228 biological regulation Effects 0.000 description 19
• 230000003247 decreasing effect Effects 0.000 description 19
• 235000019166 vitamin D Nutrition 0.000 description 19
• 239000011710 vitamin D Substances 0.000 description 19
• 150000003710 vitamin D derivatives Chemical class 0.000 description 19
• 229940046008 vitamin d Drugs 0.000 description 19
• 241001465754 Metazoa Species 0.000 description 18
• 102000005962 receptors Human genes 0.000 description 18
• 108020003175 receptors Proteins 0.000 description 18
• 108091034117 Oligonucleotide Proteins 0.000 description 17
• 210000004369 blood Anatomy 0.000 description 17
• 239000008280 blood Substances 0.000 description 17
• 230000015556 catabolic process Effects 0.000 description 17
• 238000006731 degradation reaction Methods 0.000 description 17
• -1 for example Chemical class 0.000 description 17
• 239000004055 small Interfering RNA Substances 0.000 description 17
• 241000894006 Bacteria Species 0.000 description 16
• 102000000541 Defensins Human genes 0.000 description 16
• 108010002069 Defensins Proteins 0.000 description 16
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
• 230000015572 biosynthetic process Effects 0.000 description 16
• 239000008103 glucose Substances 0.000 description 16
• 239000000243 solution Substances 0.000 description 16
• 230000000845 anti-microbial effect Effects 0.000 description 15
• 238000011161 development Methods 0.000 description 15
• 230000018109 developmental process Effects 0.000 description 15
• 230000001404 mediated effect Effects 0.000 description 15
• 208000030159 metabolic disease Diseases 0.000 description 15
• 238000010172 mouse model Methods 0.000 description 15
• 230000037361 pathway Effects 0.000 description 15
• 230000008569 process Effects 0.000 description 15
• 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 description 14
• 102000019034 Chemokines Human genes 0.000 description 14
• 108010012236 Chemokines Proteins 0.000 description 14
• 102000004877 Insulin Human genes 0.000 description 14
• 108090001061 Insulin Proteins 0.000 description 14
• 230000033115 angiogenesis Effects 0.000 description 14
• 230000002917 arthritic effect Effects 0.000 description 14
• 229940125396 insulin Drugs 0.000 description 14
• 239000000463 material Substances 0.000 description 14
• 210000002997 osteoclast Anatomy 0.000 description 14
• 102000004169 proteins and genes Human genes 0.000 description 14
• 210000003491 skin Anatomy 0.000 description 14
• 102000053642 Catalytic RNA Human genes 0.000 description 13
• 208000009386 Experimental Arthritis Diseases 0.000 description 13
• 238000001990 intravenous administration Methods 0.000 description 13
• 210000000265 leukocyte Anatomy 0.000 description 13
• 238000004519 manufacturing process Methods 0.000 description 13
• 235000018102 proteins Nutrition 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• 108090000994 Catalytic RNA Proteins 0.000 description 12
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
• 230000007815 allergy Effects 0.000 description 12
• 230000004663 cell proliferation Effects 0.000 description 12
• 229940079593 drug Drugs 0.000 description 12
• 108091092562 ribozyme Proteins 0.000 description 12
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 11
• 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 11
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
• 230000000692 anti-sense effect Effects 0.000 description 11
• 239000007943 implant Substances 0.000 description 11
• 229920000747 poly(lactic acid) Polymers 0.000 description 11
• 206010015150 Erythema Diseases 0.000 description 10
• 230000004913 activation Effects 0.000 description 10
• 238000013459 approach Methods 0.000 description 10
• 102000012265 beta-defensin Human genes 0.000 description 10
• 108050002883 beta-defensin Proteins 0.000 description 10
• 208000037976 chronic inflammation Diseases 0.000 description 10
• 238000003776 cleavage reaction Methods 0.000 description 10
• 230000001419 dependent effect Effects 0.000 description 10
• 238000005516 engineering process Methods 0.000 description 10
• 210000003414 extremity Anatomy 0.000 description 10
• 235000009200 high fat diet Nutrition 0.000 description 10
• 238000000338 in vitro Methods 0.000 description 10
• 229910052742 iron Inorganic materials 0.000 description 10
• 230000007017 scission Effects 0.000 description 10
• 239000000725 suspension Substances 0.000 description 10
• 230000008961 swelling Effects 0.000 description 10
• 238000003786 synthesis reaction Methods 0.000 description 10
• 201000001320 Atherosclerosis Diseases 0.000 description 9
• 108091027757 Deoxyribozyme Proteins 0.000 description 9
• 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 9
• 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 9
• 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 9
• 102000018568 alpha-Defensin Human genes 0.000 description 9
• 108050007802 alpha-defensin Proteins 0.000 description 9
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 9
• 125000002091 cationic group Chemical group 0.000 description 9
• 210000002683 foot Anatomy 0.000 description 9
• 210000001035 gastrointestinal tract Anatomy 0.000 description 9
• 230000009610 hypersensitivity Effects 0.000 description 9
• 229920001184 polypeptide Polymers 0.000 description 9
• 230000003248 secreting effect Effects 0.000 description 9
• 230000000699 topical effect Effects 0.000 description 9
• 239000003981 vehicle Substances 0.000 description 9
• 208000006386 Bone Resorption Diseases 0.000 description 8
• 241000283690 Bos taurus Species 0.000 description 8
• 102000004127 Cytokines Human genes 0.000 description 8
• 108090000695 Cytokines Proteins 0.000 description 8
• 108020004414 DNA Proteins 0.000 description 8
• 241000282412 Homo Species 0.000 description 8
• 102000035195 Peptidases Human genes 0.000 description 8
• 108091005804 Peptidases Proteins 0.000 description 8
• 239000004365 Protease Substances 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 230000004071 biological effect Effects 0.000 description 8
• 230000024245 cell differentiation Effects 0.000 description 8
• 210000003169 central nervous system Anatomy 0.000 description 8
• 230000006020 chronic inflammation Effects 0.000 description 8
• 235000005911 diet Nutrition 0.000 description 8
• 230000037213 diet Effects 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• 230000003053 immunization Effects 0.000 description 8
• 238000002649 immunization Methods 0.000 description 8
• 230000003902 lesion Effects 0.000 description 8
• 150000002632 lipids Chemical class 0.000 description 8
• 229920000642 polymer Polymers 0.000 description 8
• 210000004927 skin cell Anatomy 0.000 description 8
• 238000007920 subcutaneous administration Methods 0.000 description 8
• QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 8
• 235000005282 vitamin D3 Nutrition 0.000 description 8
• 239000011647 vitamin D3 Substances 0.000 description 8
• 229940021056 vitamin d3 Drugs 0.000 description 8
• 206010027476 Metastases Diseases 0.000 description 7
• 241001494479 Pecora Species 0.000 description 7
• 208000025747 Rheumatic disease Diseases 0.000 description 7
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
• 210000003719 b-lymphocyte Anatomy 0.000 description 7
• 239000000969 carrier Substances 0.000 description 7
• 238000004113 cell culture Methods 0.000 description 7
• 238000013461 design Methods 0.000 description 7
• 230000008482 dysregulation Effects 0.000 description 7
• 239000000839 emulsion Substances 0.000 description 7
• 231100000321 erythema Toxicity 0.000 description 7
• 102000049262 human DEFB4A Human genes 0.000 description 7
• 210000004408 hybridoma Anatomy 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 208000015181 infectious disease Diseases 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 239000007928 intraperitoneal injection Substances 0.000 description 7
• 235000021242 lactoferrin Nutrition 0.000 description 7
• 230000009401 metastasis Effects 0.000 description 7
• 102000039446 nucleic acids Human genes 0.000 description 7
• 108020004707 nucleic acids Proteins 0.000 description 7
• 150000007523 nucleic acids Chemical class 0.000 description 7
• 239000002773 nucleotide Substances 0.000 description 7
• 238000011160 research Methods 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
• 102100036848 C-C motif chemokine 20 Human genes 0.000 description 6
• 238000011740 C57BL/6 mouse Methods 0.000 description 6
• 208000035473 Communicable disease Diseases 0.000 description 6
• 241000588724 Escherichia coli Species 0.000 description 6
• 206010020772 Hypertension Diseases 0.000 description 6
• 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 6
• 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 6
• 102100039360 Toll-like receptor 4 Human genes 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 238000010171 animal model Methods 0.000 description 6
• 210000003423 ankle Anatomy 0.000 description 6
• 230000000844 anti-bacterial effect Effects 0.000 description 6
• 239000000427 antigen Substances 0.000 description 6
• 108091007433 antigens Proteins 0.000 description 6
• 102000036639 antigens Human genes 0.000 description 6
• 230000024279 bone resorption Effects 0.000 description 6
• 210000002808 connective tissue Anatomy 0.000 description 6
• 210000004443 dendritic cell Anatomy 0.000 description 6
• 238000011156 evaluation Methods 0.000 description 6
• 125000005647 linker group Chemical group 0.000 description 6
• 230000003211 malignant effect Effects 0.000 description 6
• 210000004379 membrane Anatomy 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 125000003729 nucleotide group Chemical group 0.000 description 6
• 210000000963 osteoblast Anatomy 0.000 description 6
• 230000002018 overexpression Effects 0.000 description 6
• 239000002243 precursor Substances 0.000 description 6
• 239000007929 subcutaneous injection Substances 0.000 description 6
• 230000004083 survival effect Effects 0.000 description 6
• 230000009885 systemic effect Effects 0.000 description 6
• 201000009030 Carcinoma Diseases 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 208000007882 Gastritis Diseases 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 5
• 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 description 5
• 101001041589 Homo sapiens Defensin-5 Proteins 0.000 description 5
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 5
• 108090001007 Interleukin-8 Proteins 0.000 description 5
• 102000016943 Muramidase Human genes 0.000 description 5
• 108010014251 Muramidase Proteins 0.000 description 5
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
• 206010033799 Paralysis Diseases 0.000 description 5
• 102000057297 Pepsin A Human genes 0.000 description 5
• 108090000284 Pepsin A Proteins 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 229920002472 Starch Polymers 0.000 description 5
• 210000001744 T-lymphocyte Anatomy 0.000 description 5
• 206010052779 Transplant rejections Diseases 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 239000004599 antimicrobial Substances 0.000 description 5
• 208000006673 asthma Diseases 0.000 description 5
• 238000001574 biopsy Methods 0.000 description 5
• 230000000903 blocking effect Effects 0.000 description 5
• 210000002449 bone cell Anatomy 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 239000002775 capsule Substances 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 208000030533 eye disease Diseases 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 239000007789 gas Substances 0.000 description 5
• 230000002496 gastric effect Effects 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 230000009368 gene silencing by RNA Effects 0.000 description 5
• 230000000762 glandular Effects 0.000 description 5
• 102000046975 human DEFB1 Human genes 0.000 description 5
• 102000055779 human DEFB103A Human genes 0.000 description 5
• 229940124644 immune regulator Drugs 0.000 description 5
• 210000001503 joint Anatomy 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 239000004325 lysozyme Substances 0.000 description 5
• 235000010335 lysozyme Nutrition 0.000 description 5
• 229960000274 lysozyme Drugs 0.000 description 5
• 230000000926 neurological effect Effects 0.000 description 5
• 230000008506 pathogenesis Effects 0.000 description 5
• 230000007170 pathology Effects 0.000 description 5
• 238000012545 processing Methods 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 238000010186 staining Methods 0.000 description 5
• 210000001258 synovial membrane Anatomy 0.000 description 5
• 210000005222 synovial tissue Anatomy 0.000 description 5
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 230000003612 virological effect Effects 0.000 description 5
• 235000019786 weight gain Nutrition 0.000 description 5
• 230000004584 weight gain Effects 0.000 description 5
• KRJOFJHOZZPBKI-KSWODRSDSA-N α-defensin-1 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@H](CSSC[C@H](NC2=O)C(O)=O)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C)C(=O)N3)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 KRJOFJHOZZPBKI-KSWODRSDSA-N 0.000 description 5
• 102000007469 Actins Human genes 0.000 description 4
• 108010085238 Actins Proteins 0.000 description 4
• 101710193402 Alpha-defensin 1 Proteins 0.000 description 4
• 208000008822 Ankylosis Diseases 0.000 description 4
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
• 206010051728 Bone erosion Diseases 0.000 description 4
• 102100021936 C-C motif chemokine 27 Human genes 0.000 description 4
• 102100021942 C-C motif chemokine 28 Human genes 0.000 description 4
• 102100023795 Elafin Human genes 0.000 description 4
• 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 description 4
• 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 description 4
• 102000004890 Interleukin-8 Human genes 0.000 description 4
• 206010023198 Joint ankylosis Diseases 0.000 description 4
• 108010063045 Lactoferrin Proteins 0.000 description 4
• 102000010445 Lactoferrin Human genes 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• 102100030417 Matrilysin Human genes 0.000 description 4
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
• 206010027925 Monoparesis Diseases 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• 108010081690 Pertussis Toxin Proteins 0.000 description 4
• 102100036154 Platelet basic protein Human genes 0.000 description 4
• 108091030071 RNAI Proteins 0.000 description 4
• 241001303601 Rosacea Species 0.000 description 4
• 206010040070 Septic Shock Diseases 0.000 description 4
• 102000012479 Serine Proteases Human genes 0.000 description 4
• 108010022999 Serine Proteases Proteins 0.000 description 4
• 102000008847 Serpin Human genes 0.000 description 4
• 108050000761 Serpin Proteins 0.000 description 4
• 238000000692 Student's t-test Methods 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 230000003321 amplification Effects 0.000 description 4
• 239000000074 antisense oligonucleotide Substances 0.000 description 4
• 238000012230 antisense oligonucleotides Methods 0.000 description 4
• 210000000544 articulatio talocruralis Anatomy 0.000 description 4
• 102000052586 bactericidal permeability increasing protein Human genes 0.000 description 4
• 108010032816 bactericidal permeability increasing protein Proteins 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 208000018631 connective tissue disease Diseases 0.000 description 4
• 210000004748 cultured cell Anatomy 0.000 description 4
• 101150047356 dec-1 gene Proteins 0.000 description 4
• 238000001514 detection method Methods 0.000 description 4
• 230000003828 downregulation Effects 0.000 description 4
• 239000008298 dragée Substances 0.000 description 4
• 210000002889 endothelial cell Anatomy 0.000 description 4
• 210000002919 epithelial cell Anatomy 0.000 description 4
• 208000006454 hepatitis Diseases 0.000 description 4
• 230000013632 homeostatic process Effects 0.000 description 4
• 230000002209 hydrophobic effect Effects 0.000 description 4
• 230000006698 induction Effects 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 4
• 229940078795 lactoferrin Drugs 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 210000003141 lower extremity Anatomy 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 230000036210 malignancy Effects 0.000 description 4
• 210000004962 mammalian cell Anatomy 0.000 description 4
• 230000000813 microbial effect Effects 0.000 description 4
• 210000001616 monocyte Anatomy 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 238000011369 optimal treatment Methods 0.000 description 4
• 210000003134 paneth cell Anatomy 0.000 description 4
• 102000040430 polynucleotide Human genes 0.000 description 4
• 108091033319 polynucleotide Proteins 0.000 description 4
• 239000002157 polynucleotide Substances 0.000 description 4
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 235000019419 proteases Nutrition 0.000 description 4
• 230000001185 psoriatic effect Effects 0.000 description 4
• 238000003757 reverse transcription PCR Methods 0.000 description 4
• 238000007363 ring formation reaction Methods 0.000 description 4
• 201000004700 rosacea Diseases 0.000 description 4
• 239000003001 serine protease inhibitor Substances 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 208000017520 skin disease Diseases 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 238000007619 statistical method Methods 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 101710154607 Azurocidin Proteins 0.000 description 3
• 102100030009 Azurocidin Human genes 0.000 description 3
• 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 3
• 102100026887 Beta-defensin 103 Human genes 0.000 description 3
• 101710125296 Beta-defensin 3 Proteins 0.000 description 3
• 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 3
• 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
• 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 3
• 108010040471 CC Chemokines Proteins 0.000 description 3
• 102000001902 CC Chemokines Human genes 0.000 description 3
• 108050006947 CXC Chemokine Proteins 0.000 description 3
• 102000019388 CXC chemokine Human genes 0.000 description 3
• 102000005600 Cathepsins Human genes 0.000 description 3
• 108010084457 Cathepsins Proteins 0.000 description 3
• 108010083700 Chemokine CCL20 Proteins 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 102100021420 Defensin-5 Human genes 0.000 description 3
• 208000007465 Giant cell arteritis Diseases 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 3
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 3
• 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 3
• 101000865479 Homo sapiens Defensin-6 Proteins 0.000 description 3
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
• 108010007622 LDL Lipoproteins Proteins 0.000 description 3
• 102000007330 LDL Lipoproteins Human genes 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 101710117809 Phospholipase A(2) Proteins 0.000 description 3
• 102100030304 Platelet factor 4 Human genes 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 201000009594 Systemic Scleroderma Diseases 0.000 description 3
• 206010042953 Systemic sclerosis Diseases 0.000 description 3
• 108091023045 Untranslated Region Proteins 0.000 description 3
• 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 3
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
• 206010047115 Vasculitis Diseases 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 208000007502 anemia Diseases 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 229940098773 bovine serum albumin Drugs 0.000 description 3
• GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 3
• 229960005084 calcitriol Drugs 0.000 description 3
• 235000020964 calcitriol Nutrition 0.000 description 3
• 239000011612 calcitriol Substances 0.000 description 3
• 108010007004 cathelin Proteins 0.000 description 3
• 208000015114 central nervous system disease Diseases 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• 238000010168 coupling process Methods 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 239000006071 cream Substances 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 210000000805 cytoplasm Anatomy 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 230000007123 defense Effects 0.000 description 3
• 230000007812 deficiency Effects 0.000 description 3
• 230000006735 deficit Effects 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 235000019197 fats Nutrition 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 210000000224 granular leucocyte Anatomy 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 231100000283 hepatitis Toxicity 0.000 description 3
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
• 102000018511 hepcidin Human genes 0.000 description 3
• 108060003558 hepcidin Proteins 0.000 description 3
• 210000003630 histaminocyte Anatomy 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 206010022000 influenza Diseases 0.000 description 3
• 230000000968 intestinal effect Effects 0.000 description 3
• 210000000936 intestine Anatomy 0.000 description 3
• 150000002500 ions Chemical class 0.000 description 3
• 230000002147 killing effect Effects 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 210000001872 metatarsal bone Anatomy 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 238000000329 molecular dynamics simulation Methods 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• 208000010125 myocardial infarction Diseases 0.000 description 3
• 239000002105 nanoparticle Substances 0.000 description 3
• 230000003472 neutralizing effect Effects 0.000 description 3
• 238000013116 obese mouse model Methods 0.000 description 3
• 230000027758 ovulation cycle Effects 0.000 description 3
• 239000005022 packaging material Substances 0.000 description 3
• 244000052769 pathogen Species 0.000 description 3
• 229940111202 pepsin Drugs 0.000 description 3
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 230000035935 pregnancy Effects 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000002062 proliferating effect Effects 0.000 description 3
• 208000002574 reactive arthritis Diseases 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 208000023504 respiratory system disease Diseases 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• WTJDAUWOECZENF-OZWITMHCSA-N smap-29 Chemical compound NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(C)C)CC1=CC=C(O)C=C1 WTJDAUWOECZENF-OZWITMHCSA-N 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 210000000434 stratum corneum Anatomy 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 210000002437 synoviocyte Anatomy 0.000 description 3
• 206010043207 temporal arteritis Diseases 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 201000008827 tuberculosis Diseases 0.000 description 3
• 230000007998 vessel formation Effects 0.000 description 3
• XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 2
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
• OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
• SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
• 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
• 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• 102000013563 Acid Phosphatase Human genes 0.000 description 2
• 108010051457 Acid Phosphatase Proteins 0.000 description 2
• 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
• 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 2
• 101710193400 Alpha-defensin 2 Proteins 0.000 description 2
• 108090000644 Angiozyme Proteins 0.000 description 2
• 206010003267 Arthritis reactive Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 208000030767 Autoimmune encephalitis Diseases 0.000 description 2
• 102100033735 Bactericidal permeability-increasing protein Human genes 0.000 description 2
• 101710125314 Beta-defensin 1 Proteins 0.000 description 2
• 102100037437 Beta-defensin 1 Human genes 0.000 description 2
• 102100026886 Beta-defensin 104 Human genes 0.000 description 2
• 101710125298 Beta-defensin 2 Proteins 0.000 description 2
• 101710125300 Beta-defensin 4 Proteins 0.000 description 2
• 101710176951 Beta-defensin 4A Proteins 0.000 description 2
• 102100038326 Beta-defensin 4A Human genes 0.000 description 2
• 208000010392 Bone Fractures Diseases 0.000 description 2
• 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 2
• 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
• 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
• 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 2
• 201000006474 Brain Ischemia Diseases 0.000 description 2
• 241000030939 Bubalus bubalis Species 0.000 description 2
• 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 2
• 101710112538 C-C motif chemokine 27 Proteins 0.000 description 2
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
• 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 2
• 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
• 206010006895 Cachexia Diseases 0.000 description 2
• 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 108010052500 Calgranulin A Proteins 0.000 description 2
• 108010052495 Calgranulin B Proteins 0.000 description 2
• 241000282465 Canis Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 206010008120 Cerebral ischaemia Diseases 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 108010078777 Colistin Proteins 0.000 description 2
• 208000034656 Contusions Diseases 0.000 description 2
• 201000003883 Cystic fibrosis Diseases 0.000 description 2
• 101710178508 Defensin 3 Proteins 0.000 description 2
• 108010016626 Dipeptides Proteins 0.000 description 2
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 108010015972 Elafin Proteins 0.000 description 2
• 241000287828 Gallus gallus Species 0.000 description 2
• 208000018522 Gastrointestinal disease Diseases 0.000 description 2
• 102000004878 Gelsolin Human genes 0.000 description 2
• 108090001064 Gelsolin Proteins 0.000 description 2
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
• 201000005569 Gout Diseases 0.000 description 2
• 102100021186 Granulysin Human genes 0.000 description 2
• 101710168479 Granulysin Proteins 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 241000711549 Hepacivirus C Species 0.000 description 2
• 108010033040 Histones Proteins 0.000 description 2
• 101000871785 Homo sapiens Bactericidal permeability-increasing protein Proteins 0.000 description 2
• 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 2
• 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 2
• 101001048718 Homo sapiens Elafin Proteins 0.000 description 2
• 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 2
• 101000830386 Homo sapiens Neutrophil defensin 3 Proteins 0.000 description 2
• 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 2
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 208000001718 Immediate Hypersensitivity Diseases 0.000 description 2
• 102000014150 Interferons Human genes 0.000 description 2
• 108010050904 Interferons Proteins 0.000 description 2
• 102100026236 Interleukin-8 Human genes 0.000 description 2
• 208000003456 Juvenile Arthritis Diseases 0.000 description 2
• 208000011200 Kawasaki disease Diseases 0.000 description 2
• 241000713666 Lentivirus Species 0.000 description 2
• 108010051335 Lipocalin-2 Proteins 0.000 description 2
• 102000013519 Lipocalin-2 Human genes 0.000 description 2
• 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
• 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
• 108090000855 Matrilysin Proteins 0.000 description 2
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
• 102100021126 N-formyl peptide receptor 2 Human genes 0.000 description 2
• 101710091942 N-formyl peptide receptor 2 Proteins 0.000 description 2
• 102100024761 Neutrophil defensin 3 Human genes 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• 206010033307 Overweight Diseases 0.000 description 2
• 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 2
• 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 2
• 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 2
• 101710084411 POU domain, class 2, transcription factor 2 Proteins 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 108090000526 Papain Proteins 0.000 description 2
• 208000037273 Pathologic Processes Diseases 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• 101710195957 Platelet basic protein Proteins 0.000 description 2
• 108090000778 Platelet factor 4 Proteins 0.000 description 2
• 206010036049 Polycystic ovaries Diseases 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 102100032446 Protein S100-A7 Human genes 0.000 description 2
• 102100032442 Protein S100-A8 Human genes 0.000 description 2
• 102100032420 Protein S100-A9 Human genes 0.000 description 2
• 241000589516 Pseudomonas Species 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 208000033464 Reiter syndrome Diseases 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 206010038934 Retinopathy proliferative Diseases 0.000 description 2
• 102000006382 Ribonucleases Human genes 0.000 description 2
• 108010083644 Ribonucleases Proteins 0.000 description 2
• 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• 229920002125 Sokalan® Polymers 0.000 description 2
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
• 208000001106 Takayasu Arteritis Diseases 0.000 description 2
• 206010043540 Thromboangiitis obliterans Diseases 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 206010044248 Toxic shock syndrome Diseases 0.000 description 2
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 2
• 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 2
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
• 206010045240 Type I hypersensitivity Diseases 0.000 description 2
• 208000024780 Urticaria Diseases 0.000 description 2
• 108091008605 VEGF receptors Proteins 0.000 description 2
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
• 108020000999 Viral RNA Proteins 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 239000008351 acetate buffer Substances 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 2
• 101150066984 aml gene Proteins 0.000 description 2
• 208000003455 anaphylaxis Diseases 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 210000000628 antibody-producing cell Anatomy 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 208000010216 atopic IgE responsiveness Diseases 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 108091008324 binding proteins Proteins 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• BRRSZIMJXSPBER-GPKCLSBHSA-N bmap-27 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CN)C1=CC=CC=C1 BRRSZIMJXSPBER-GPKCLSBHSA-N 0.000 description 2
• WMFBKFIMNMRQAY-MVPIGCMHSA-N bmap-28 Chemical compound CC[C@H](C)[C@@H](C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]1N(C(=O)CNC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CN)[C@@H](C)CC)CCC1 WMFBKFIMNMRQAY-MVPIGCMHSA-N 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 229940112869 bone morphogenetic protein Drugs 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 206010008118 cerebral infarction Diseases 0.000 description 2
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
• 208000026106 cerebrovascular disease Diseases 0.000 description 2
• KAFGYXORACVKTE-UEDJBKKJSA-N chembl503567 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(N1)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)C1=CC=C(O)C=C1 KAFGYXORACVKTE-UEDJBKKJSA-N 0.000 description 2
• 239000002975 chemoattractant Substances 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 239000002537 cosmetic Substances 0.000 description 2
• VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
• 230000016396 cytokine production Effects 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 239000005547 deoxyribonucleotide Substances 0.000 description 2
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 208000016097 disease of metabolism Diseases 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• 230000002222 downregulating effect Effects 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 2
• 238000005538 encapsulation Methods 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 230000003628 erosive effect Effects 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 208000014951 hematologic disease Diseases 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 229940066919 hepcidin Drugs 0.000 description 2
• 208000010726 hind limb paralysis Diseases 0.000 description 2
• 210000000548 hind-foot Anatomy 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 238000003364 immunohistochemistry Methods 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 230000015788 innate immune response Effects 0.000 description 2
• 210000005007 innate immune system Anatomy 0.000 description 2
• 229940079322 interferon Drugs 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 description 2
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
• 231100000518 lethal Toxicity 0.000 description 2
• 230000001665 lethal effect Effects 0.000 description 2
• 238000012417 linear regression Methods 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 108091005601 modified peptides Proteins 0.000 description 2
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
• 210000004400 mucous membrane Anatomy 0.000 description 2
• JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 2
• 230000002956 necrotizing effect Effects 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 210000000944 nerve tissue Anatomy 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 235000016709 nutrition Nutrition 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 201000002740 oral squamous cell carcinoma Diseases 0.000 description 2
• 230000011164 ossification Effects 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000009054 pathological process Effects 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 239000000816 peptidomimetic Substances 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 201000006292 polyarteritis nodosa Diseases 0.000 description 2
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
• XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 2
• 230000002516 postimmunization Effects 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 108010032966 protegrin-1 Proteins 0.000 description 2
• 208000017443 reproductive system disease Diseases 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 201000000980 schizophrenia Diseases 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 201000009890 sinusitis Diseases 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 235000015424 sodium Nutrition 0.000 description 2
• HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 2
• LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
• 239000001433 sodium tartrate Substances 0.000 description 2
• 229960002167 sodium tartrate Drugs 0.000 description 2
• 235000011004 sodium tartrates Nutrition 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 210000001179 synovial fluid Anatomy 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 238000002626 targeted therapy Methods 0.000 description 2
• 210000002435 tendon Anatomy 0.000 description 2
• 230000008467 tissue growth Effects 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 150000003626 triacylglycerols Chemical class 0.000 description 2
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 230000005951 type IV hypersensitivity Effects 0.000 description 2
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 229960005486 vaccine Drugs 0.000 description 2
• 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
• 229940088594 vitamin Drugs 0.000 description 2
• 229930003231 vitamin Natural products 0.000 description 2
• 235000013343 vitamin Nutrition 0.000 description 2
• 239000011782 vitamin Substances 0.000 description 2
• 102000009310 vitamin D receptors Human genes 0.000 description 2
• 108050000156 vitamin D receptors Proteins 0.000 description 2
• 150000003722 vitamin derivatives Chemical class 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• OFMQLVRLOGHAJI-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18 Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 OFMQLVRLOGHAJI-FGHAYEPSSA-N 0.000 description 1
• JWICNZAGYSIBAR-LEEGLKINSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2s)-3-carboxy-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-4-carboxy-1-[[2-[[2-[[2-[[(2s)-1-[[(1s)-1-carboxy-4-(diaminomethylideneamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)N)CC1=CC=CC=C1 JWICNZAGYSIBAR-LEEGLKINSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
• YJIYWYAMZFVECX-UHFFFAOYSA-N 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetic acid acetyloxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O YJIYWYAMZFVECX-UHFFFAOYSA-N 0.000 description 1
• HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
• LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
• JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 1
• 108020003589 5' Untranslated Regions Proteins 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 206010000060 Abdominal distension Diseases 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 102400001318 Adrenomedullin Human genes 0.000 description 1
• 101800004616 Adrenomedullin Proteins 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 206010058285 Allergy to arthropod bite Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 101710193394 Alpha-defensin 3 Proteins 0.000 description 1
• 101710193395 Alpha-defensin 4 Proteins 0.000 description 1
• 206010001935 American trypanosomiasis Diseases 0.000 description 1
• 208000030760 Anaemia of chronic disease Diseases 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 206010002199 Anaphylactic shock Diseases 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 102100022987 Angiogenin Human genes 0.000 description 1
• 101710190945 Angiogenin-4 Proteins 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 108010024284 Apolipoprotein C-II Proteins 0.000 description 1
• 102100039998 Apolipoprotein C-II Human genes 0.000 description 1
• 108010056301 Apolipoprotein C-III Proteins 0.000 description 1
• 102100030970 Apolipoprotein C-III Human genes 0.000 description 1
• 102100029470 Apolipoprotein E Human genes 0.000 description 1
• 101710095339 Apolipoprotein E Proteins 0.000 description 1
• 108010060219 Apolipoprotein E2 Proteins 0.000 description 1
• 108010060215 Apolipoprotein E3 Proteins 0.000 description 1
• 102000008128 Apolipoprotein E3 Human genes 0.000 description 1
• 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
• 108010071619 Apolipoproteins Proteins 0.000 description 1
• 102000007592 Apolipoproteins Human genes 0.000 description 1
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 108090000254 Aureolysin Proteins 0.000 description 1
• 206010071155 Autoimmune arthritis Diseases 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
• 108010073001 BMAP-27 Proteins 0.000 description 1
• 108010073005 BMAP-28 Proteins 0.000 description 1
• 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 102100037841 Beta-defensin 105 Human genes 0.000 description 1
• 102100037913 Beta-defensin 106 Human genes 0.000 description 1
• 102100039817 Beta-defensin 118 Human genes 0.000 description 1
• 101710125297 Beta-defensin 5 Proteins 0.000 description 1
• 101710125302 Beta-defensin 6 Proteins 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 208000033386 Buerger disease Diseases 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• 102100023701 C-C motif chemokine 18 Human genes 0.000 description 1
• 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
• 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
• 102100021933 C-C motif chemokine 25 Human genes 0.000 description 1
• 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
• 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 1
• 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
• 102100025250 C-X-C motif chemokine 14 Human genes 0.000 description 1
• 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
• 102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 1
• 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
• 101150102665 CCL20 gene Proteins 0.000 description 1
• 101001125997 Caenorhabditis elegans Intracellular phospholipase A2 Proteins 0.000 description 1
• 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
• 102400000870 Calcitermin Human genes 0.000 description 1
• 101800005167 Calcitermin Proteins 0.000 description 1
• 102400000113 Calcitonin Human genes 0.000 description 1
• 108060001064 Calcitonin Proteins 0.000 description 1
• 102100024654 Calcitonin gene-related peptide type 1 receptor Human genes 0.000 description 1
• 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
• 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 206010007134 Candida infections Diseases 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 101000859017 Capra hircus Cathelicidin-2 Proteins 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 101710140438 Cathelicidin antimicrobial peptide Proteins 0.000 description 1
• 101710115644 Cathelicidin-2 Proteins 0.000 description 1
• 108090000712 Cathepsin B Proteins 0.000 description 1
• 102000004225 Cathepsin B Human genes 0.000 description 1
• 102100025975 Cathepsin G Human genes 0.000 description 1
• 108090000617 Cathepsin G Proteins 0.000 description 1
• 108090000625 Cathepsin K Proteins 0.000 description 1
• 102000004171 Cathepsin K Human genes 0.000 description 1
• 102400001321 Cathepsin L Human genes 0.000 description 1
• 108090000624 Cathepsin L Proteins 0.000 description 1
• 206010008190 Cerebrovascular accident Diseases 0.000 description 1
• 208000024699 Chagas disease Diseases 0.000 description 1
• 208000009043 Chemical Burns Diseases 0.000 description 1
• 208000018380 Chemical injury Diseases 0.000 description 1
• 108010083675 Chemokine CCL27 Proteins 0.000 description 1
• 108010055166 Chemokine CCL5 Proteins 0.000 description 1
• 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
• 102000009410 Chemokine receptor Human genes 0.000 description 1
• 108050000299 Chemokine receptor Proteins 0.000 description 1
• 201000005019 Chlamydia pneumonia Diseases 0.000 description 1
• 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
• 208000010126 Chondromatosis Diseases 0.000 description 1
• 208000019591 Chondromyxoid fibroma Diseases 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 102000010792 Chromogranin A Human genes 0.000 description 1
• 108010038447 Chromogranin A Proteins 0.000 description 1
• 102000010791 Chromogranin B Human genes 0.000 description 1
• 108010038439 Chromogranin B Proteins 0.000 description 1
• 102000007345 Chromogranins Human genes 0.000 description 1
• 108010007718 Chromogranins Proteins 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• 102100024539 Chymase Human genes 0.000 description 1
• 108090000227 Chymases Proteins 0.000 description 1
• 102100025566 Chymotrypsin-like protease CTRL-1 Human genes 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 208000002330 Congenital Heart Defects Diseases 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000195493 Cryptophyta Species 0.000 description 1
• 241001559589 Cullen Species 0.000 description 1
• 102000015833 Cystatin Human genes 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 102400000361 DCD-1 Human genes 0.000 description 1
• 101800003946 DCD-1 Proteins 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 101710178517 Defensin-5 Proteins 0.000 description 1
• 102100029790 Defensin-6 Human genes 0.000 description 1
• 101710129420 Defensin-like peptide Proteins 0.000 description 1
• 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 208000020401 Depressive disease Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 206010052337 Diastolic dysfunction Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
• 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
• 206010013700 Drug hypersensitivity Diseases 0.000 description 1
• 208000032928 Dyslipidaemia Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010014522 Embolism venous Diseases 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 206010014666 Endocarditis bacterial Diseases 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 208000037487 Endotoxemia Diseases 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 101800002934 Enkelytin Proteins 0.000 description 1
• 102000057955 Eosinophil Cationic Human genes 0.000 description 1
• 101710191360 Eosinophil cationic protein Proteins 0.000 description 1
• 102100023688 Eotaxin Human genes 0.000 description 1
• XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010039659 FALL 39 Proteins 0.000 description 1
• 108010039471 Fas Ligand Protein Proteins 0.000 description 1
• 101800000974 Fibrinopeptide A Proteins 0.000 description 1
• 102400000525 Fibrinopeptide A Human genes 0.000 description 1
• 101800003778 Fibrinopeptide B Proteins 0.000 description 1
• 102400001063 Fibrinopeptide B Human genes 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 241000192016 Finegoldia magna Species 0.000 description 1
• 208000004262 Food Hypersensitivity Diseases 0.000 description 1
• 206010016946 Food allergy Diseases 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
• 102000013818 Fractalkine Human genes 0.000 description 1
• 208000001034 Frostbite Diseases 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 241000276438 Gadus morhua Species 0.000 description 1
• 101100222215 Gallus gallus CATHL2 gene Proteins 0.000 description 1
• 101000859022 Gallus gallus Cathelicidin-3 Proteins 0.000 description 1
• 206010017711 Gangrene Diseases 0.000 description 1
• 208000007569 Giant Cell Tumors Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 1
• 208000005232 Glossitis Diseases 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 229920002683 Glycosaminoglycan Polymers 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 102000001398 Granzyme Human genes 0.000 description 1
• 108060005986 Granzyme Proteins 0.000 description 1
• 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 208000023329 Gun shot wound Diseases 0.000 description 1
• 102100034445 HCLS1-associated protein X-1 Human genes 0.000 description 1
• 101710200673 HCLS1-associated protein X-1 Proteins 0.000 description 1
• 102000055206 HMGN2 Human genes 0.000 description 1
• 108700010011 HMGN2 Proteins 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 241000590002 Helicobacter pylori Species 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
• 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 108010019494 Histatins Proteins 0.000 description 1
• 102000006492 Histatins Human genes 0.000 description 1
• 102000017286 Histone H2A Human genes 0.000 description 1
• 108050005231 Histone H2A Proteins 0.000 description 1
• 101000885708 Homo sapiens Beta-defensin 118 Proteins 0.000 description 1
• 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 description 1
• 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
• 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
• 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 description 1
• 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 description 1
• 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
• 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 1
• 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
• 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
• 101000858068 Homo sapiens C-X-C motif chemokine 14 Proteins 0.000 description 1
• 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
• 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 1
• 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
• 101000760563 Homo sapiens Calcitonin gene-related peptide type 1 receptor Proteins 0.000 description 1
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
• 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
• 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 1
• 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
• 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
• 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
• 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 description 1
• 101001090713 Homo sapiens L-lactate dehydrogenase A chain Proteins 0.000 description 1
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
• 101000918983 Homo sapiens Neutrophil defensin 1 Proteins 0.000 description 1
• 101000929203 Homo sapiens Neutrophil defensin 4 Proteins 0.000 description 1
• 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 1
• 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
• 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
• 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
• LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 208000002682 Hyperkalemia Diseases 0.000 description 1
• 208000013038 Hypocalcemia Diseases 0.000 description 1
• 208000019025 Hypokalemia Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 208000031814 IgA Vasculitis Diseases 0.000 description 1
• 208000024781 Immune Complex disease Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
• 229940122355 Insulin sensitizer Drugs 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 206010022971 Iron Deficiencies Diseases 0.000 description 1
• 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• 102000001399 Kallikrein Human genes 0.000 description 1
• 108060005987 Kallikrein Proteins 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• 150000008575 L-amino acids Chemical class 0.000 description 1
• FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
• 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• 108010028554 LDL Cholesterol Proteins 0.000 description 1
• 208000034693 Laceration Diseases 0.000 description 1
• 101800004361 Lactoferricin-B Proteins 0.000 description 1
• 208000007811 Latex Hypersensitivity Diseases 0.000 description 1
• 108010028275 Leukocyte Elastase Proteins 0.000 description 1
• 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
• 208000017170 Lipid metabolism disease Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 206010025327 Lymphopenia Diseases 0.000 description 1
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• 108060003100 Magainin Proteins 0.000 description 1
• 208000017660 Magnesium metabolism disease Diseases 0.000 description 1
• 235000019759 Maize starch Nutrition 0.000 description 1
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 208000001145 Metabolic Syndrome Diseases 0.000 description 1
• 208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
• 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 206010028331 Muscle rupture Diseases 0.000 description 1
• 206010050031 Muscle strain Diseases 0.000 description 1
• 208000023178 Musculoskeletal disease Diseases 0.000 description 1
• 241000186359 Mycobacterium Species 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 241000204031 Mycoplasma Species 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 108090000973 Myeloblastin Proteins 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• ZBJNZFQKYZCUJU-PAHFEQBRSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide Polymers CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O ZBJNZFQKYZCUJU-PAHFEQBRSA-N 0.000 description 1
• SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 206010029098 Neoplasm skin Diseases 0.000 description 1
• 102100029494 Neutrophil defensin 1 Human genes 0.000 description 1
• 102400001060 Neutrophil defensin 2 Human genes 0.000 description 1
• 101800000287 Neutrophil defensin 2 Proteins 0.000 description 1
• 102100036348 Neutrophil defensin 4 Human genes 0.000 description 1
• 102100033174 Neutrophil elastase Human genes 0.000 description 1
• NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
• 108010053775 Nisin Proteins 0.000 description 1
• 108020003217 Nuclear RNA Proteins 0.000 description 1
• 102000043141 Nuclear RNA Human genes 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 108010093625 Opioid Peptides Proteins 0.000 description 1
• 102000001490 Opioid Peptides Human genes 0.000 description 1
• 208000004179 Oral Leukoplakia Diseases 0.000 description 1
• 206010048685 Oral infection Diseases 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 208000001715 Osteoblastoma Diseases 0.000 description 1
• 208000031964 Other metabolic disease Diseases 0.000 description 1
• 101000859019 Ovis aries Cathelicidin-2 Proteins 0.000 description 1
• 108010066857 PMAP-36 Proteins 0.000 description 1
• 108010066849 PMAP-37 Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
• 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 206010034016 Paronychia Diseases 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 108010043958 Peptoids Proteins 0.000 description 1
• KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 201000011252 Phenylketonuria Diseases 0.000 description 1
• 102100026918 Phospholipase A2 Human genes 0.000 description 1
• 101710096328 Phospholipase A2 Proteins 0.000 description 1
• 229940124034 Phospholipase C inhibitor Drugs 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
• 108010093965 Polymyxin B Proteins 0.000 description 1
• 108010040201 Polymyxins Proteins 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
• 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
• 101710151005 Prophenin-2 Proteins 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
• 206010063562 Radiation skin injury Diseases 0.000 description 1
• 206010037779 Radiculopathy Diseases 0.000 description 1
• 101000599054 Rattus norvegicus Interleukin-6 receptor subunit beta Proteins 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 208000021063 Respiratory fume inhalation disease Diseases 0.000 description 1
• 206010038848 Retinal detachment Diseases 0.000 description 1
• 102000003661 Ribonuclease III Human genes 0.000 description 1
• 108010057163 Ribonuclease III Proteins 0.000 description 1
• 206010039251 Rubber sensitivity Diseases 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 241000277263 Salmo Species 0.000 description 1
• 206010048908 Seasonal allergy Diseases 0.000 description 1
• 102000004002 Secretory Leukocyte Peptidase Inhibitor Human genes 0.000 description 1
• 108010082545 Secretory Leukocyte Peptidase Inhibitor Proteins 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010040943 Skin Ulcer Diseases 0.000 description 1
• 206010040844 Skin exfoliation Diseases 0.000 description 1
• 206010072170 Skin wound Diseases 0.000 description 1
• 208000032140 Sleepiness Diseases 0.000 description 1
• 102000005157 Somatostatin Human genes 0.000 description 1
• 108010056088 Somatostatin Proteins 0.000 description 1
• 206010041349 Somnolence Diseases 0.000 description 1
• 208000006045 Spondylarthropathies Diseases 0.000 description 1
• 201000002661 Spondylitis Diseases 0.000 description 1
• 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 241000193996 Streptococcus pyogenes Species 0.000 description 1
• 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
• 241000272534 Struthio camelus Species 0.000 description 1
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 206010042496 Sunburn Diseases 0.000 description 1
• 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
• 101100244894 Sus scrofa PR39 gene Proteins 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
• 206010053615 Thermal burn Diseases 0.000 description 1
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 108010046075 Thymosin Proteins 0.000 description 1
• 102000007501 Thymosin Human genes 0.000 description 1
• UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 description 1
• 102100035000 Thymosin beta-4 Human genes 0.000 description 1
• 102000057032 Tissue Kallikreins Human genes 0.000 description 1
• 108700022175 Tissue Kallikreins Proteins 0.000 description 1
• 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
• 102000002689 Toll-like receptor Human genes 0.000 description 1
• 108020000411 Toll-like receptor Proteins 0.000 description 1
• 241000159243 Toxicodendron radicans Species 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108020004566 Transfer RNA Proteins 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 102000001400 Tryptase Human genes 0.000 description 1
• 108060005989 Tryptase Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
• 206010064390 Tumour invasion Diseases 0.000 description 1
• 206010054000 Type II hypersensitivity Diseases 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 208000010399 Wasting Syndrome Diseases 0.000 description 1
• 208000021017 Weight Gain Diseases 0.000 description 1
• 241000289690 Xenarthra Species 0.000 description 1
• OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
• HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
• HUXIAXQSTATULQ-UHFFFAOYSA-N [6-bromo-3-[(2-methoxyphenyl)carbamoyl]naphthalen-2-yl] dihydrogen phosphate Chemical compound COC1=CC=CC=C1NC(=O)C1=CC2=CC(Br)=CC=C2C=C1OP(O)(O)=O HUXIAXQSTATULQ-UHFFFAOYSA-N 0.000 description 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000005299 abrasion Methods 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• DGOBMKYRQHEFGQ-UHFFFAOYSA-L acid green 5 Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 DGOBMKYRQHEFGQ-UHFFFAOYSA-L 0.000 description 1
• 229960005339 acitretin Drugs 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 210000005006 adaptive immune system Anatomy 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 229940040563 agaric acid Drugs 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 238000010976 amide bond formation reaction Methods 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000022400 anemia due to chronic disease Diseases 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 108010072788 angiogenin Proteins 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000003527 anti-angiogenesis Effects 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 230000000665 anti-chemotactic effect Effects 0.000 description 1
• 230000001986 anti-endotoxic effect Effects 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 238000010420 art technique Methods 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 235000021053 average weight gain Nutrition 0.000 description 1
• RHISNKCGUDDGEG-UHFFFAOYSA-N bactenecin Chemical compound CCC(C)C1NC(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C(CCCN=C(N)N)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(N)CCCN=C(N)N)CSSCC(C(=O)NC(CCCN=C(N)N)C(O)=O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC1=O RHISNKCGUDDGEG-UHFFFAOYSA-N 0.000 description 1
• 108010016341 bactenecin Proteins 0.000 description 1
• 208000009361 bacterial endocarditis Diseases 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 239000007982 barbital buffer Substances 0.000 description 1
• 108700041737 bcl-2 Genes Proteins 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229960002938 bexarotene Drugs 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
• 208000024330 bloating Diseases 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 230000015624 blood vessel development Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 208000019664 bone resorption disease Diseases 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 208000034526 bruise Diseases 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000004900 c-terminal fragment Anatomy 0.000 description 1
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
• 229960004015 calcitonin Drugs 0.000 description 1
• 150000001668 calcitriol derivatives Chemical class 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 208000022458 calcium metabolism disease Diseases 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000009400 cancer invasion Effects 0.000 description 1
• 201000003984 candidiasis Diseases 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229960001631 carbomer Drugs 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 125000004432 carbon atom Chemical group C* 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000009134 cell regulation Effects 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 210000003850 cellular structure Anatomy 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 208000002849 chondrocalcinosis Diseases 0.000 description 1
• 208000019069 chronic childhood arthritis Diseases 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229960003346 colistin Drugs 0.000 description 1
• 230000001332 colony forming effect Effects 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000009514 concussion Effects 0.000 description 1
• 208000028831 congenital heart disease Diseases 0.000 description 1
• 108010035886 connective tissue-activating peptide Proteins 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000009519 contusion Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 201000005637 crescentic glomerulonephritis Diseases 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 238000012136 culture method Methods 0.000 description 1
• 239000004148 curcumin Substances 0.000 description 1
• 229940109262 curcumin Drugs 0.000 description 1
• 235000012754 curcumin Nutrition 0.000 description 1
• 108050004038 cystatin Proteins 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 239000007857 degradation product Substances 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
• 239000000412 dendrimer Substances 0.000 description 1
• 229920000736 dendritic polymer Polymers 0.000 description 1
• 239000004053 dental implant Substances 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 230000035618 desquamation Effects 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 229950006137 dexfosfoserine Drugs 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
• 206010062952 diffuse panbronchiolitis Diseases 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 208000010643 digestive system disease Diseases 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 229910000397 disodium phosphate Inorganic materials 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 230000006334 disulfide bridging Effects 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 201000005311 drug allergy Diseases 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 239000000428 dust Substances 0.000 description 1
• 230000004821 effect on bone Effects 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 230000003246 elastolytic effect Effects 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 206010014665 endocarditis Diseases 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000007515 enzymatic degradation Effects 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
• 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 229940117360 ethyl pyruvate Drugs 0.000 description 1
• 229960002199 etretinate Drugs 0.000 description 1
• HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 210000000416 exudates and transudate Anatomy 0.000 description 1
• 229960000301 factor viii Drugs 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000008713 feedback mechanism Effects 0.000 description 1
• 231100000562 fetal loss Toxicity 0.000 description 1
• MYRIFIVQGRMHRF-OECXYHNASA-N fibrinopeptide b Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 MYRIFIVQGRMHRF-OECXYHNASA-N 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 229940126864 fibroblast growth factor Drugs 0.000 description 1
• 235000019688 fish Nutrition 0.000 description 1
• 239000000834 fixative Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000020932 food allergy Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 208000018685 gastrointestinal system disease Diseases 0.000 description 1
• 108091008053 gene clusters Proteins 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 230000030279 gene silencing Effects 0.000 description 1
• 238000012226 gene silencing method Methods 0.000 description 1
• 102000034356 gene-regulatory proteins Human genes 0.000 description 1
• 108091006104 gene-regulatory proteins Proteins 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 230000004190 glucose uptake Effects 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 102000035122 glycosylated proteins Human genes 0.000 description 1
• 108091005608 glycosylated proteins Proteins 0.000 description 1
• XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 201000003911 head and neck carcinoma Diseases 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 229940037467 helicobacter pylori Drugs 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
• 108010037536 heparanase Proteins 0.000 description 1
• 229940051250 hexylene glycol Drugs 0.000 description 1
• 238000013537 high throughput screening Methods 0.000 description 1
• 238000013427 histology analysis Methods 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 230000005745 host immune response Effects 0.000 description 1
• 102000054350 human CHI3L1 Human genes 0.000 description 1
• 102000048466 human DEFA5 Human genes 0.000 description 1
• 102000050514 human DEFA6 Human genes 0.000 description 1
• 102000055848 human LDHA Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
• 230000000705 hypocalcaemia Effects 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 208000036260 idiopathic disease Diseases 0.000 description 1
• 125000001841 imino group Chemical group [H]N=* 0.000 description 1
• 210000001822 immobilized cell Anatomy 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000002998 immunogenetic effect Effects 0.000 description 1
• 230000009851 immunogenic response Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000000937 inactivator Effects 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 201000007119 infective endocarditis Diseases 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
• 229940096397 interleukin-8 Drugs 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000004922 lacquer Substances 0.000 description 1
• 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 1
• CFFMZOZGXDAXHP-HOKBLYKWSA-N lactoferricin Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@H](C(=O)N1)[C@@H](C)O)=O)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CFFMZOZGXDAXHP-HOKBLYKWSA-N 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 201000005391 latex allergy Diseases 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000011268 leukocyte chemotaxis Effects 0.000 description 1
• 229940051132 light green sf yellowish Drugs 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
• 231100001023 lymphopenia Toxicity 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 229960003511 macrogol Drugs 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 210000004373 mandible Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000002175 menstrual effect Effects 0.000 description 1
• 230000005906 menstruation Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 210000001237 metamyelocyte Anatomy 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 230000003641 microbiacidal effect Effects 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 206010063344 microscopic polyangiitis Diseases 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000002062 molecular scaffold Substances 0.000 description 1
• 229920000344 molecularly imprinted polymer Polymers 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 230000037211 monthly cycles Effects 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 210000005088 multinucleated cell Anatomy 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 208000017445 musculoskeletal system disease Diseases 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• 108700021654 myb Genes Proteins 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 210000005012 myelin Anatomy 0.000 description 1
• 210000003887 myelocyte Anatomy 0.000 description 1
• YKQOSKADJPQZHB-YNWHQGOSSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1s)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-YNWHQGOSSA-N 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• 201000009240 nasopharyngitis Diseases 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 230000000955 neuroendocrine Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• GRZXCHIIZXMEPJ-HTLKCAKFSA-N neutrophil peptide-2 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@@H](N)CSSC[C@H](NC2=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C)C(=O)N3)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 GRZXCHIIZXMEPJ-HTLKCAKFSA-N 0.000 description 1
• 239000004309 nisin Substances 0.000 description 1
• 235000010297 nisin Nutrition 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 229950001933 opebacan Drugs 0.000 description 1
• 239000003399 opiate peptide Substances 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 206010030983 oral lichen planus Diseases 0.000 description 1
• 201000008557 oral mucosa leukoplakia Diseases 0.000 description 1
• 229940126578 oral vaccine Drugs 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 210000004409 osteocyte Anatomy 0.000 description 1
• 208000003388 osteoid osteoma Diseases 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 208000025661 ovarian cyst Diseases 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 229930192851 perforin Natural products 0.000 description 1
• 208000028169 periodontal disease Diseases 0.000 description 1
• 230000008823 permeabilization Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 150000004713 phosphodiesters Chemical class 0.000 description 1
• 239000003371 phospholipase C inhibitor Substances 0.000 description 1
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
• USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000010399 physical interaction Effects 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• ZPWVBRGFVGXRKZ-DMZHRTQBSA-N pmap-23 Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=CC=C1 ZPWVBRGFVGXRKZ-DMZHRTQBSA-N 0.000 description 1
• 208000030773 pneumonia caused by chlamydia Diseases 0.000 description 1
• 201000004338 pollen allergy Diseases 0.000 description 1
• 229920001432 poly(L-lactide) Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
• 229960005266 polymyxin b Drugs 0.000 description 1
• 229960003548 polymyxin b sulfate Drugs 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 108010027884 porcine myeloid antibacterial peptide 23 Proteins 0.000 description 1
• 235000020004 porter Nutrition 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 208000024896 potassium deficiency disease Diseases 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 239000000955 prescription drug Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000004647 pro-inflammatory pathway Effects 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• KZAZIWVZJLUFCN-DPAFCJMGSA-N protegrin 3 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(N1)=O)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C(C)C)C1=CC=C(O)C=C1 KZAZIWVZJLUFCN-DPAFCJMGSA-N 0.000 description 1
• 108010032978 protegrin-3 Proteins 0.000 description 1
• 108010032968 protegrin-4 Proteins 0.000 description 1
• DUDXZJRHGONAAZ-ZFOLPASKSA-N protegrin-4 Chemical compound C([C@@H]1NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C3=CC=CC=C3NC=1)C(=O)N[C@H](C(N2)=O)[C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 DUDXZJRHGONAAZ-ZFOLPASKSA-N 0.000 description 1
• 108010032974 protegrin-5 Proteins 0.000 description 1
• JCKSZPLZVLHFMU-UEDJBKKJSA-N protegrin-5 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(N1)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C(C)C)C1=CC=C(O)C=C1 JCKSZPLZVLHFMU-UEDJBKKJSA-N 0.000 description 1
• 238000012514 protein characterization Methods 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 229940030793 psoriasin Drugs 0.000 description 1
• 238000011158 quantitative evaluation Methods 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 230000026267 regulation of growth Effects 0.000 description 1
• 230000018277 regulation of iron ion transport Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000004264 retinal detachment Effects 0.000 description 1
• 150000004492 retinoid derivatives Chemical class 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 230000001359 rheumatologic effect Effects 0.000 description 1
• 108010092136 ribosomal protein S30 Proteins 0.000 description 1
• 229940100486 rice starch Drugs 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 206010040400 serum sickness Diseases 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 230000037321 sleepiness Effects 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 235000010288 sodium nitrite Nutrition 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000012064 sodium phosphate buffer Substances 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
• 229960000553 somatostatin Drugs 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 201000005671 spondyloarthropathy Diseases 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 208000017572 squamous cell neoplasm Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000000528 statistical test Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 231100000617 superantigen Toxicity 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000012353 t test Methods 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229960000565 tazarotene Drugs 0.000 description 1
• 108010034266 theta-defensin Proteins 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
• 108010079996 thymosin beta(4) Proteins 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 230000005029 transcription elongation Effects 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 230000001810 trypsinlike Effects 0.000 description 1
• 239000001974 tryptic soy broth Substances 0.000 description 1
• 108010050327 trypticase-soy broth Proteins 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 238000010396 two-hybrid screening Methods 0.000 description 1
• 238000001521 two-tailed test Methods 0.000 description 1
• 230000009959 type I hypersensitivity Effects 0.000 description 1
• 230000008026 type II hypersensitivity Effects 0.000 description 1
• 230000028063 type III hypersensitivity Effects 0.000 description 1
• 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
• 210000001692 type a synoviocyte Anatomy 0.000 description 1
• 210000002192 type b synovial cell Anatomy 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 239000013598 vector Substances 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 208000034280 venom allergy Diseases 0.000 description 1
• 208000004043 venous thromboembolism Diseases 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• 229940045997 vitamin a Drugs 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1